AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6808657 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin 3 g
Number of subjects: 12
Study 6808657 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin (all doses)
Number of subjects: 12
Study 31122224 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion intervention in women's groups (three sessions using WHO Hearing and Ear Care Training Resource Basic Level)
Number of subjects: 508
Study 31122224 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion intervention in women's groups
Number of subjects: 508
Study 31122224 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 508
Study 28901823 — intervention group
Group type: EXPERIMENTAL
Intervention: Comic flyer
Number of subjects: 265
Study 28901823 — intervention group
Group type: COMPARATOR
Intervention: CDC flyer
Number of subjects: 265
Study 27814710 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 80 ppm as an adjunctive therapy for severe malaria
Number of subjects: 180
Study 27814710 — intervention group
Group type: COMPARATOR
Intervention: Room air placebo
Number of subjects: 180
Study 27814710 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 180
Study 23918627 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-choice condition (participants chose hand and target freely)
Number of subjects: 0
Study 23918627 — intervention group
Group type: COMPARATOR
Intervention: Hand-specified condition (hand was specified)
Number of subjects: 0
Study 23918627 — intervention group
Group type: COMPARATOR
Intervention: Target-specified condition (target was specified)
Number of subjects: 0
Study 22296508 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention with a depression care manager offering algorithm-based depression care
Number of subjects: 599
Study 22296508 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 599
Study 22296508 — intervention group
Group type: EXPERIMENTAL
Intervention: High and persistent depression symptoms
Number of subjects: 599
Study 22296508 — intervention group
Group type: EXPERIMENTAL
Intervention: Low and declining depression symptoms
Number of subjects: 599
Study 19563288 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap without vertical releasing incisions (envelope-type flap)
Number of subjects: 32
Study 19563288 — intervention group
Group type: COMPARATOR
Intervention: Coronally advanced flap with vertical releasing incisions
Number of subjects: 32
Study 19563288 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques (CAF with and without vertical releasing incisions)
Number of subjects: 32
Study 19563288 — intervention group
Group type: EXPERIMENTAL
Intervention: Envelope-type CAF
Number of subjects: 32
Study 17463151 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue food color measurement
Number of subjects: 8
Study 17463151 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose breath hydrogen testing
Number of subjects: 8
Study 17463151 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiopaque marker
Number of subjects: 8
Study 15976799 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 122
Study 15976799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 15976799 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab or Placebo (with preprocedural hyperglycemia)
Number of subjects: 122
Study 15976799 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab or Placebo (without preprocedural hyperglycemia)
Number of subjects: 122
Study 15976799 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 122
Study 11828905 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracker-assisted centration (20 eyes)
Number of subjects: 25
Study 11828905 — intervention group
Group type: COMPARATOR
Intervention: Manual centration (18 eyes)
Number of subjects: 25
Study 11828905 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracker-assisted centration
Number of subjects: 25
Study 11828905 — intervention group
Group type: COMPARATOR
Intervention: Manual centration
Number of subjects: 25
Study 10077718 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis/self-hypnosis (5 sessions, half an hour each, weekly intervals)
Number of subjects: 0
Study 10077718 — intervention group
Group type: COMPARATOR
Intervention: Behavior therapy (2 sessions, half an hour each, weekly intervals)
Number of subjects: 0
Study 10077718 — intervention group
Group type: COMPARATOR
Intervention: Talks to the doctor (2 sessions, half an hour each, weekly intervals)
Number of subjects: 0
Study 8750042 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional set (two sets of instructions)
Number of subjects: 45
Study 8750042 — intervention group
Group type: COMPARATOR
Intervention: Room air hyperventilation
Number of subjects: 45
Study 8750042 — intervention group
Group type: COMPARATOR
Intervention: 5% CO2 inhalation
Number of subjects: 45
Study 8750042 — intervention group
Group type: COMPARATOR
Intervention: 7% CO2 inhalation
Number of subjects: 45
Study 2202317 — intervention group
Group type: EXPERIMENTAL
Intervention: BioFilm hydrogel dressing
Number of subjects: 90
Study 2202317 — intervention group
Group type: COMPARATOR
Intervention: Hydrocolloid dressing (HCD)
Number of subjects: 90
Study 7150057 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic acetazolamide
Number of subjects: 0
Study 7150057 — intervention group
Group type: COMPARATOR
Intervention: Brand-name acetazolamide (Diamox)
Number of subjects: 0
Study 31539061 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (0.075 mg/kg/day) and glucocorticoids (0.6-1.0 mg/kg/day of prednisolone)
Number of subjects: 26
Study 30403988 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-combination brinzolamide 1%/brimonidine 0.2% (BBFC), 1 drop 3 times daily for 4 weeks
Number of subjects: 125
Study 30403988 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control group), 1 drop 3 times daily for 4 weeks
Number of subjects: 125
Study 25599300 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative widespread pain sensitivity measured by pressure pain thresholds (PPTs) at the forearm using an algometer.
Number of subjects: 493
Study 23549693 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training alone (GR)
Number of subjects: 125
Study 23549693 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined resistance and endurance training (GCON)
Number of subjects: 125
Study 23549693 — intervention group
Group type: COMPARATOR
Intervention: Control group (GC)
Number of subjects: 125
Study 21455724 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate salt (10 mg, twice daily until day seven of age)
Number of subjects: 294
Study 21455724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study 19592861 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Clinical Reasoning (GCR)
Number of subjects: 225
Study 19592861 — intervention group
Group type: COMPARATOR
Intervention: Classic Case Discussions
Number of subjects: 225
Study 17702031 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole (50mg twice daily)
Number of subjects: 537
Study 17702031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 537
Study 15054473 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0
Study 15054473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15054473 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study 10960824 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-pulse dye laser at 595 nm with dynamic cooling device (DCD)
Number of subjects: 18
Study 10960824 — intervention group
Group type: COMPARATOR
Intervention: Long-pulse dye laser at 595 nm without dynamic cooling device (DCD)
Number of subjects: 18
Study 10960824 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-pulse dye laser at 595 nm
Number of subjects: 18
Study 9050957 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine 2.5‐3 mg/kg per day
Number of subjects: 17
Study 9050957 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 17
Study 1415030 — intervention group
Group type: EXPERIMENTAL
Intervention: Advocacy services from trained advocates
Number of subjects: 141
Study 1415030 — intervention group
Group type: COMPARATOR
Intervention: No advocacy services (Control)
Number of subjects: 141
Study 4008145 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance load of 5.59 joules/pedal rev/kg BW
Number of subjects: 19
Study 4008145 — intervention group
Group type: COMPARATOR
Intervention: Wingate setting of 4.41 joules/pedal rev/kg BW
Number of subjects: 19
Study 31661693 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Observation Therapy (AOT) for 20 min before 10 min language therapy daily for 4 weeks
Number of subjects: 42
Study 31661693 — intervention group
Group type: COMPARATOR
Intervention: Conventional language therapy for 30 min twice daily for 4 weeks
Number of subjects: 42
Study 29564547 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum containing Phyllanthus emblica (PE) fruit extract
Number of subjects: 20
Study 29564547 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 20
Study 25963336 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (ICS) treatment
Number of subjects: 110
Study 25142820 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast dissolving oral film formulation of flupentixol dihydrochloride (2% HPMC)
Number of subjects: 0
Study 25142820 — intervention group
Group type: COMPARATOR
Intervention: Commercially available oral tablets of flupentixol dihydrochloride
Number of subjects: 0
Study 22442395 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 0
Study 22442395 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 22442395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20533148 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard interdisciplinary training programme
Number of subjects: 159
Study 20533148 — intervention group
Group type: EXPERIMENTAL
Intervention: BBS-trainer interdisciplinary training programme
Number of subjects: 159
Study 18215558 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Ignition Interlock Programme (AIIP)
Number of subjects: 0
Study 18215558 — intervention group
Group type: COMPARATOR
Intervention: Conventional licence revocation
Number of subjects: 0
Study 16188958 — intervention group
Group type: EXPERIMENTAL
Intervention: Family based behavioural treatment for obese children for two years
Number of subjects: 68
Study 16188958 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 68
Study 12974147 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg three times daily)
Number of subjects: 39
Study 12974147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 11187559 — intervention group
Group type: EXPERIMENTAL
Intervention: Wilson score method for calculating confidence intervals for the number needed to treat
Number of subjects: 0
Study 11187559 — intervention group
Group type: COMPARATOR
Intervention: Usual asymptotic method for calculating confidence intervals for the absolute risk reduction
Number of subjects: 0
Study 8865525 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (10-12 weeks)
Number of subjects: 21
Study 1497688 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-acetyldigoxin tablets
Number of subjects: 12
Study 1497688 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-acetyldigoxin oral solution
Number of subjects: 12
Study 373786 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (0.4 mg)
Number of subjects: 17
Study 373786 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (0.5 mg)
Number of subjects: 17
Study 373786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31147361 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular porcine collagen implant
Number of subjects: 85
Study 31147361 — intervention group
Group type: COMPARATOR
Intervention: Gluteus maximus myocutaneous flap
Number of subjects: 85
Study 28604556 — intervention group
Group type: COMPARATOR
Intervention: NeuGcGM3-based vaccine (200 μg) administered every 2 weeks for 5 doses, followed by monthly reimmunizations to complete 15 doses, combined with Montanide ISA51 as adjuvant treatment.
Number of subjects: 0
Study 28604556 — intervention group
Group type: COMPARATOR
Intervention: NeuGcGM3-based vaccine
Number of subjects: 0
Study 25879726 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component web-based intervention incorporating objective monitoring and graphical feedback of physical activity
Number of subjects: 488
Study 25879726 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective monitoring plus web-based graphical feedback
Number of subjects: 488
Study 25879726 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of physical activity using a paper diary
Number of subjects: 488
Study 25879726 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 488
Study 23784727 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training (CT) combined with cholinesterase inhibitors (ChEIs)
Number of subjects: 32
Study 23784727 — intervention group
Group type: COMPARATOR
Intervention: Non-specific cognitive treatment combined with cholinesterase inhibitors (ChEIs)
Number of subjects: 32
Study 21737214 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal methamphetamine (0, 5, 10, 20 and 30 mg)
Number of subjects: 8
Study 21737214 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam XR (0 and 1 mg/day)
Number of subjects: 8
Study 19474796 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil (10 mg)
Number of subjects: 42
Study 19474796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 17357380 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 4 g/d
Number of subjects: 0
Study 17357380 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 6 g/d
Number of subjects: 0
Study 17357380 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 8 g/d
Number of subjects: 0
Study 17357380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16387250 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus on Kids (FOK) intervention
Number of subjects: 1131
Study 16387250 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1131
Study 14517691 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate dose of IFN-alpha (2.5 MU/m² per day)
Number of subjects: 109
Study 14517691 — intervention group
Group type: COMPARATOR
Intervention: High dose of IFN-alpha (5 MU/m² per day)
Number of subjects: 109
Study 14517691 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intermediate and high dose)
Number of subjects: 109
Study 10566652 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment for 4 months
Number of subjects: 22
Study 10566652 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 22
Study 7676795 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40
Study 7676795 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 40
Study 2178522 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential terbutaline (0.25 mg subcutaneously followed by another 0.25 mg subcutaneously)
Number of subjects: 8
Study 2178522 — intervention group
Group type: COMPARATOR
Intervention: Single treatment (normal saline)
Number of subjects: 8
Study 6988003 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 24
Study 6988003 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 24
Study 6988003 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 24
Study 29807349 — intervention group
Group type: EXPERIMENTAL
Intervention: Dampening appraisals during memory recall (Study One)
Number of subjects: 0
Study 29807349 — intervention group
Group type: COMPARATOR
Intervention: Amplifying appraisals during memory recall (Study One)
Number of subjects: 0
Study 29807349 — intervention group
Group type: EXPERIMENTAL
Intervention: Dampening appraisals during anticipation (Study Two)
Number of subjects: 0
Study 29807349 — intervention group
Group type: COMPARATOR
Intervention: Amplifying appraisals during anticipation (Study Two)
Number of subjects: 0
Study 27928809 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical expulsive therapy (tamsulosin 0.4 mg daily at night, furosemide 20mg, spironolactone 50mg in a single morning dose, potassium magnesium citrate 20Meq three times a day for 12 weeks)
Number of subjects: 100
Study 27928809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 27928809 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical expulsive therapy
Number of subjects: 100
Study 23503044 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone re-education (TRE) on the day before colonoscopy
Number of subjects: 605
Study 23503044 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TRE)
Number of subjects: 605
Study 22866288 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately loaded implants
Number of subjects: 30
Study 22866288 — intervention group
Group type: COMPARATOR
Intervention: Early loaded implants
Number of subjects: 30
Study 22866288 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 20001450 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral posaconazole suspension as antifungal prophylaxis
Number of subjects: 0
Study 20001450 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 18164144 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (400/100mg bid, Sinemet) with VBRT
Number of subjects: 161
Study 18164144 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (400/100mg bid, Sinemet)
Number of subjects: 161
Study 18164144 — intervention group
Group type: COMPARATOR
Intervention: Placebo with VBRT
Number of subjects: 161
Study 16041270 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 1.5 mg/day
Number of subjects: 583
Study 16041270 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 3 mg/day
Number of subjects: 583
Study 16041270 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) 2 g/day
Number of subjects: 583
Study 12486651 — intervention group
Group type: EXPERIMENTAL
Intervention: RITM (remifentanil and intrathecal morphine) anesthesia
Number of subjects: 24
Study 12486651 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl-based anesthesia (control)
Number of subjects: 24
Study 10433573 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic regimens (ciprofloxacin, ofloxacin, norfloxacin, trimethoprim‐sulfamethoxazole, nitrofurantoin)
Number of subjects: 3108
Study 10433573 — intervention group
Group type: EXPERIMENTAL
Intervention: Not using a diaphragm
Number of subjects: 3108
Study 10433573 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for > or = 3 days
Number of subjects: 3108
Study 10433573 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogen not 'other'
Number of subjects: 3108
Study 10433573 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom duration of < 2 days
Number of subjects: 3108
Study 10433573 — intervention group
Group type: EXPERIMENTAL
Intervention: African American race
Number of subjects: 3108
Study 10433573 — intervention group
Group type: EXPERIMENTAL
Intervention: K. pneumoniae
Number of subjects: 3108
Study 10433573 — intervention group
Group type: EXPERIMENTAL
Intervention: 'Other' pathogens
Number of subjects: 3108
Study 10433573 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of pyuria (> or = 10 WBCs per high‐power field)
Number of subjects: 3108
Study 7725851 — intervention group
Group type: EXPERIMENTAL
Intervention: L-asparaginase (L-Ase) with human antithrombin III (AT III) concentrates as adjuvant treatment
Number of subjects: 0
Study 7725851 — intervention group
Group type: COMPARATOR
Intervention: L-asparaginase (L-Ase)
Number of subjects: 0
Study 1971596 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 425
Study 1971596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 425
Study 7458684 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 300 mg daily
Number of subjects: 32
Study 31759909 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g of a legume-based food product administered daily for three months (5 days on, 2 days off)
Number of subjects: 60
Study 30704463 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (B)
Number of subjects: 58
Study 30704463 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine (LB)
Number of subjects: 58
Study 27715376 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2% Rosuvastatin gel
Number of subjects: 90
Study 27715376 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2% Atorvastatin gel
Number of subjects: 90
Study 27715376 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 90
Study 25194004 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol (1 μg/d for 3 months, uptitrated to 2 µg/d if tolerated)
Number of subjects: 43
Study 25194004 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 43
Study 25194004 — intervention group
Group type: COMPARATOR
Intervention: Nonparicalcitol therapy
Number of subjects: 43
Study 23514842 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil (AZL-M) 40 mg
Number of subjects: 884
Study 23514842 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil (AZL-M) 80 mg
Number of subjects: 884
Study 23514842 — intervention group
Group type: COMPARATOR
Intervention: Ramipril (RAM) 10 mg
Number of subjects: 884
Study 21872682 — intervention group
Group type: COMPARATOR
Intervention: Secnidazole (2g)
Number of subjects: 96
Study 21872682 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentha crispa (2g)
Number of subjects: 96
Study 19413933 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed reminder two weeks prior to visit
Number of subjects: 5338
Study 19413933 — intervention group
Group type: COMPARATOR
Intervention: No mailed reminder
Number of subjects: 5338